![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety, pharmacokinetic, pharmacodynamics and viral data after 6-weeks of dosing with TLR7 agonist RO7020531 in chronic hepatitis B patients
|
|
|
AASLD 2019 Nov 8-12 Boston
Reported by Jules Levin
Man-Fung Yuen1, RozalinaBalabanska2, KoshAgarwal3, YonghongZhu4, Joseph F. Grippo5, YuyanJin4, QiudiJiang4, Miriam Triyatni6, RuchiUpmanyu7, Katerina Glavini6, Tomas Racek6, Edward J. Gane8
1Queen Mary Hospital, Hong Kong; 2. AcibademCity Clinic, TokudaHospital, Sofia; 3. Institute of Liver Studies, Kings College Hospital, London; 4. Roche Innovation Center Shanghai 5. Roche Innovation Center New York; 6. Roche Innovation Center Basel; 7. Roche Innovation Center Welwyn; 8. Auckland Clinical Studies
![1202191](../images/120219/120219-3/1202191.gif)
![1202192](../images/120219/120219-3/1202192.gif)
![1202193](../images/120219/120219-3/1202193.gif)
![1202194](../images/120219/120219-3/1202194.gif)
![1202195](../images/120219/120219-3/1202195.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|